Brief: BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)
12/01/2026 12:43
Jan 12 (Reuters) - Brainsway Ltd BWAY.TA: BRAINSWAY ANNOUNCES FDA APPROVAL OF NEUROLIEF’S PROLIV™RX NEUROMODULATION SYSTEM FOR MAJOR DEPRESSIVE DISORDER (MDD) Source text: ID:nGNX7MCBST Further company coverage: BWAY.TA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brainsway
See all newsBrief: Brainsway Presents Positive Data From Largest Real-World Study Of Deep Tms™ In Patients With Comorbid Ptsd And Major Depressive Disorder
Brief: Brainsway Announces Minority-Stake Investment In Hopemark Health
Brief: Brainsway Announces New Minority-Stake Investment In Canadian Provider, Brainstim Health Inc.
Brief: Brainsway Announces Change In ADS-To-Ordinary Share Ratio
Brief: BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)